enow.com Web Search

  1. Ads

    related to: new blood pressure procedure fda

Search results

  1. Results from the WOW.Com Content Network
  2. US FDA approves Medtronic's blood pressure treatment ... - AOL

    www.aol.com/news/us-fda-approves-medtronics...

    (Reuters) - The U.S. Food and Drug Administration on Friday approved the use of Medtronic's treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be ...

  3. Could blood pressure be better controlled with new FDA ...

    www.aol.com/could-blood-pressure-better...

    A new FDA-approved treatment for high blood pressure targeting the nerves of the kidneys has been studied in Austin and is now being done at the Heart Hospital of Austin. On March 27, the hospital ...

  4. US FDA approves Otsuka's blood pressure treatment ... - AOL

    www.aol.com/news/us-fda-approves-otsukas-blood...

    (Reuters) - The U.S. Food and Drug Administration (FDA) approved the use of a device made by an Otsuka Holdings unit in a type of surgery to treat high blood pressure, the company said on Wednesday.

  5. Renal sympathetic denervation - Wikipedia

    en.wikipedia.org/wiki/Renal_Sympathetic_Denervation

    This was often successful in reducing blood pressure but due to its non-selective nature the side effects of the procedure were poorly tolerated. Side effects included orthostatic hypotension, palpitations, anhydrosis, intestinal disturbances, loss of ejaculation, thoracic duct injuries and atelectasis. [ 10 ]

  6. Baroreflex activation therapy - Wikipedia

    en.wikipedia.org/wiki/Baroreflex_activation_therapy

    Baroreflex activation therapy is an approach to treating high blood pressure and the symptoms of heart failure. It uses an implanted device to electrically stimulate baroreceptors in the carotid sinus region. This elicits a reflex response through the sympathetic and vagal nervous systems that reduces blood pressure.

  7. Moxonidine - Wikipedia

    en.wikipedia.org/wiki/Moxonidine

    Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.

  1. Ads

    related to: new blood pressure procedure fda